Healthcare
Emergent BioSolutions Inc.(EBS)
Live Price
Offline$8.39
+1.82% today
1Y Change
+23.62%
Window
Jun 27, 2025 โ Jun 22, 2026
- Market Cap
- $470.00M
- Revenue Growth
- -28.8%
- EPS Growth
- +127.2%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 27, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Emergent BioSolutions Inc. (EBS) is a Healthcare stock with a market cap of $470.00M and listed on NYSE. The stock last traded around $8.39 and up 23.6% across the available one-year price window (Jun 27, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of -28.8%, EPS growth of +127.2%, a dividend yield of 0.0%. What stands out right now is revenue -28.8%, EPS +127.2%, free cash flow +338.0% with operating margin 10.5% and ROIC -14.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EBS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-28.8% vs +7.6% peer median
Operating Margin
Below sector median
+10.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q2 2026 was reported on May 29, 2026 with an EPS surprise of +24.3%.
The operating picture looks softer than before
Revenue is at -28.8% and EPS is at +127.2%, with operating margin around 10.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 May 29, 2026 | +24.3% | -6.9% | -11.5% | โ |
Q2 2026 Apr 30, 2026 | +184.0% | +2.9% | +10.9% | +10.8% |
Q1 2026 Mar 24, 2026 | -150.0% | +2.5% | +3.6% | +3.5% |
Benchmark Edge
EBS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EBS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EBS Max Drawdown
-44.24%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EBS and SPY.
Company Overview
Emergent BioSolutions Inc.
New York Stock Exchange
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
- Leadership
- Joseph C. Papa Jr.
- IPO Date
- Nov 15, 2006
- Employees
- 900
- Street Address
- 400 Professional Drive
- Mailing
- Gaithersburg, MD, 20879
- Region
- Gaithersburg, MD, US
- Reporting Currency
- USD
- Investor Line
- 240 631 3200
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 5.3
- Price/Sales
- 0.7
- Price/Book
- 0.9
Growth
- Revenue
- -28.8%
- EPS
- +127.2%
- Free Cash Flow
- +338.0%
Profitability
- Gross Margin
- 44.4%
- Operating Margin
- 10.5%
- Net Margin
- -1.3%
- ROE
- -1.6%
- ROIC
- -14.9%
Balance Sheet
- Debt/Equity
- 1.10
- Current Ratio
- 4.29
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.